Current Status of Tissue Engineering in Stress Urinary Incontinence  by Wang, Hung-Jen
MINI  REVIEW
Urol Sci 2011;22(2):53−57
©2011 Taiwan Urological Association. Published by Elsevier Taiwan LLC. 53
Current Status of Tissue Engineering in Stress Urinary 
Incontinence
Hung-Jen Wang*
Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 
 Kaohsiung, Taiwan
Over 200 million people worldwide suffer from incontinence, which is a condition 
associated with a social impact and a reduced quality of life. The results of pharma-
cotherapy for stress urinary incontinence (SUI) have been disappointing. The poten-
tial of stem cell (SC) therapy for the regenerative repair of a deficient sphincter is 
currently at the forefront of incontinence research. As an alternative, injection of 
autologous adult SCs into the periurethral area provides a less-invasive treatment 
alternative compared with traditional surgical intervention. Cells used in the treat-
ment of SUI include muscle- and adipose-derived SCs. In animal studies, injection of 
intraurethral SCs has improved sphincter function. Short-term clinical results dem-
onstrate that SUI can effectively be treated with autologous SCs. The present data 
support the conclusion that this therapeutic concept represents an elegant and 
minimally invasive modality for treating SUI.
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1.  Introduction
Urinary incontinence is common in women. More than 
200 million people worldwide live with incontinence.1 
Incontinence frequently occurs from middle age on-
wards and is associated with a reduced quality of life.2 
Stress urinary incontinence (SUI) is the most common 
type of urinary incontinence.3 SUI arises when bladder 
pressure exceeds the urethral pressure in the setting 
of a sudden increase in intra-abdominal forces. This in-
crease might occur because of an anatomical change or 
because of neuromuscular compromise to the sphincter 
itself.1 The risk factors for SUI include parity, age, and 
obesity.3–5 Most researchers believe that SUI varies 
between the extremes of urethral hypermobility and 
intrinsic sphincter deficiency.6
Treatments for SUI include nonsurgical and surgical 
options. In nonsurgical treatment, pelvic floor muscle 
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training usually serves as the first-line treatment and 
provides promising results. However, careful patient se-
lection is mandatory to achieve satisfactory results, and 
in some cases, improvement is limited.7 Currently, du-
loxetine, a selective serotonin/norepinephrine reuptake 
inhibitor, is the only medical treatment available for SUI 
in Europe,8 but it is not approved in the USA as an indi-
cation for SUI. Surgery provides more promising out-
comes in treating stress incontinence.9,10 Except for the 
more-invasive sling procedures, bulking agents injected 
near the bladder neck improve urinary incontinence by 
increasing coaptation along the urethra and improving 
outlet resistance. The use of polytetrafluoroethylene, 
autologous ear chondrocytes, carbon beads, silicone 
particles, and bovine collagen as bulking agents yields 
short-term success in treating SUI.11–15 However, use of 
bulking agents can result in chronic inflammatory reac-
tions, a foreign-body giant-cell response, particle migration, 
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periurethral abscess, erosion of the urinary bladder or 
urethra, or obstruction with urinary retention.16–18
Recent advances in tissue engineering offer new 
therapeutic opportunities in the field of SUI in which 
conventional treatment modalities may be inadequate. 
Tissue engineering uses the principles of cell transplan-
tation, material science, and biomedical engineering to 
develop biological substitutes that can restore and 
maintain normal function of damaged or lost tissues and 
organs.19 The potential of stem cell (SC) therapy for the 
regenerative repair of a deficient sphincter is currently 
at the forefront of incontinence research.20
2.  Cell sources for Injection Therapy of SUI
The ideal cells for tissue engineering should be easily 
procured using minimally invasive techniques, provide 
sufficient quantities of cells from normal tissues, prolif-
erate quickly in a well-regulated manner, exhibit multilin-
eage differentiation capabilities to regenerate multiple 
tissues, and be capable of being readily transplanted into 
an autologous host.19 Cell-based therapies and tissue 
engineering are most often associated with the use of 
multipotent SCs. There are two types of SCs potentially 
useful for therapeutic treatment: embryonic SCs and adult 
SCs. Although they both exhibit the remarkable properties 
of being able to self-renew and differentiate into a large 
number of special cell types,21 embryonic SCs are lim-
ited by problems of cell regulation and ethical consider-
ations.22 Adult SCs have no significant ethical issues 
related to their use, and there are different sources of 
adult SCs. Bone marrow was the first source reported to 
contain mesenchymal SCs (MSCs), which are capable of 
differentiating into adipogenic, osteogenic, chondro-
genic, and myogenic cells.23–25 However, for clinical use, 
bone marrow may be detrimental because of the highly 
invasive procedure required for harvest, a low yield of 
MSCs upon processing, and a decline in the MSC number 
and differentiation potential with increased age.23,26 
Muscle-derived SCs (MDSCs) and adipose-derived SCs 
(ADSCs) are advantageous because they can be obtained 
and expanded to abundant quantities of cells using sim-
ple procedures.27,28
3.  MDSCs
Muscle-derived cell therapy, often referred to as myo-
blast transfer therapy, is hindered by numerous limi-
tations. It was found that < 3% of cells, using traditional 
methods of obtaining muscle precursor cells, are still 
present 1 hour after being injected into muscle.29 Selec-
tion of specific muscle-derived cell populations or the 
control of inflammation can be used as an approach to 
improve cell survival after both myoblast transplantation 
and a myoblast-mediated ex vivo gene transfer approach.30 
Such studies led to extensive investigations into the 
developmental origins of skeletal muscle progenitor 
cells.28,31 MDSCs display a remarkable regenerative ca-
pacity, total survival, and ability to restore function com-
pared with commonly recognized and abundant striated 
muscle precursor “myoblast” cells.32 MDSCs also have 
an improved transplantation capacity with the ability to 
undergo long-term proliferation, self-renewal, and 
multipotent differentiation.33 MDSCs are uniquely dif-
ferent from fibroblasts and muscle cells since MDSCs 
will fuse to form post-mitotic multinucleated myo-
tubes.34 This limits the persistent expansion of injected 
cells and the risk of outlet obstruction that has been ob-
served with other cell sources such as fibroblasts.35 Finally, 
MDSCs form myotubes and myofibers that become inner-
vated into the host muscle.35 Therefore, MDSCs are 
physiologically capable of improving urethral sphincter 
function instead of only serving as a bulking agent.36
The feasibility of this concept has been demon-
strated in rodent models of SUI.37,38 An injection of in-
traurethral MDSC improves urethral sphincter function 
in a rat model of intrinsic sphincter deficiency. An in-
crease in the leak point pressure was statistically significant 
after 4 weeks in the MDSC-injected group compared 
with saline-injected cauterized rats. No alteration in 
bladder function occurred with either cauterization or 
MDSC injections. A histological examination showed that 
MDSCs had integrated within the striated muscle layer 
of the cauterized mid-urethra. In addition, the striated 
muscle layer of the MDSC-injected urethra was contigu-
ous and had more nerves than the cauterized urethra 
injected with only a saline solution.38 Those results sug-
gested that MDSCs might have the ability for multipo-
tent differentiation in the host urethra and have the 
capability to elicit a paracrine effect resulting in a more-
complete muscle-nerve healing response.
4.  ADSCs
Recently, multipotent MSCs were identified within the 
stromal vascular fraction of human adipose tissue. 
Clonal studies of adipose-derived multipotent cells dem-
onstrated that such cells exhibit multilineage differentia-
tion into adipogenic, myogenic, chondrogenic, osteogenic, 
and neurogenic cells; therefore, these cells are com-
monly referred to as adipose-derived SCs.27,39 Rodriguez 
et al. demonstrated that adipose-derived cells have the 
potential to differentiate into functional smooth muscle 
cells; importantly, smooth muscle-differentiated cells 
but not their precursors exhibit the functional ability to 
contract and relax in direct response to pharmacologic 
agents.40 The same group also demonstrated that ADSCs 
injected periurethrally exhibit in vivo differentiation into 
smooth muscle; and therefore, show promise as a po-
tential cell source for SUI treatment.41 In another study, 
the feasibility of ADSC use was suggested through 
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reports on improvements in leak point pressure and ure-
thral function in a rat model of SUI when animals were 
injected with ADSCs in conjunction with biodegradable 
microbeads as a carrier.42 By providing a potential cost-
effective source for reconstruction in the urology field, 
cell therapy using MDSCs and ADSCs is emerging as a 
promising technology for treating SUI.
5.  Direct Myofiber Implantation
Skeletal muscle satellite cells are quiescent mononucle-
ated myogenic cells, located between the sarcolemma 
and basement membrane of terminally differentiated 
muscle fibers. These are normally quiescent in adult mus-
cles but act as a reserve population of cells, able to prolif-
erate in response to injury and give rise to regenerated 
muscle and additional satellite cells. The recent discov-
ery of a number of markers expressed by satellite cells 
provided evidence that satellite cells, which had long 
been presumed to be a homogeneous population of 
muscle SCs, might not be equivalent. It is possible that a 
subpopulation of satellite cells may be derived from a 
more primitive SC.43,44 Satellite cell-derived muscle pre-
cursor cells can be used to repair and regenerate dam-
aged or myopathic skeletal muscle or to act as vectors 
for gene therapy. Based on this concept, a study was 
conducted in which myofibers were directly implanted 
with non-manipulated satellite cells.45 The rationale be-
hind this strategy was the fact that the small number of 
satellite cells contained in each muscle fiber (2–10 ˜  105 
cells/g muscle) is sufficient to completely reconstitute 
all myofibers lost after injury.43,44,46 Each female pig un-
derwent a muscle biopsy from which myofibers were iso-
lated and immediately implanted into the proximal third 
of the urethra. It was found that the myofiber cores act 
as a reservoir of satellite cells which immediately prolif-
erates after isolation and fusion in 2–3 weeks to form 
numerous myotubes replacing the parental myofibers 
within the urethra. Urodynamic studies have shown that 
implantation of a muscle strip around the proximal ure-
thra results in a distinct pressure peak in the initial seg-
ment of the urethral pressure profilometry. Implantation 
of myofiber strips generated a pressure peak that de-
creased after curarization and reappeared 60 min later, 
revealing that this action was tonic and under neural 
control. This has potential clinical value as a means to 
create an additional striated urethral sphincter.
6.  Results of Current Clinical Studies
The first clinical studies of SUI became available in 2007. 
Strasser et al. reported their comparison of 63 patients 
(42 women and 21 men) undergoing an autologous myo-
blast and fibroblast injection versus 28 patients under-
going a collagen injection for SUI.47 Specifically, cultures 
of autologous fibroblasts and myoblasts were obtained 
from skeletal muscle biopsies, taken from the left arm. 
Autologous cells were cultured in a “current good manu-
facturing practice” laboratory according to strict stan-
dard operating procedures. Myoblasts and fibroblasts 
(two types of muscle-derived autologous cells) were iso-
lated from the muscle biopsies and grown separately. 
The fibroblasts and myoblasts were then filled into sepa-
rate sterile syringes and transported to the operating 
room. At the beginning of the cell injection, a transure-
thral ultrasound probe (8 channel, 15–20 MHz) was 
carefully inserted into the urethra. The urethral wall and 
the rhabdosphincter were visualized. The myoblast sus-
pension was directly injected into the omega-shaped 
rhabdosphincter to promote its regeneration while the 
fibroblast/collagen suspension was injected into the 
submucosa to treat atrophy and promote a sealing ef-
fect. In the collagen-injection only group, despite a sig-
nificant decrease in incontinence scores and increase in 
the Incontinence Quality of Life score, these results did 
not translate into clinical improvement, and only 10% of 
patients were cured of incontinence. In contrast, 85% of 
the SC-related group was cured of incontinence at the 
12-month follow-up. The thicknesses of the urethra and 
rhabdosphincter and the contractility of the rhab-
dosphincter improved postoperatively in the SC-related 
group. Other similar studies have demonstrated the ef-
ficacy of treatment with larger patient numbers and 
longer follow-up periods (Table 1). Mitterberger et al. 
reported an 89% cure rate among 20 female SUI patients 
using the same protocol.48 In another study including 
123 female SUI patients, 79% were completely conti-
nent at the 1-year follow-up and 13% reported substan-
tial improvement.49 The efficacy and safety of application 
of a similar protocol for treatment in post-prostatectomy 
urinary incontinence were also assessed. Of the 63 pa-
tients, 41 (65%) were continent 12 months after implan-
tation of cells. The Incontinence Quality of Life scores 
significantly improved post-injection.50 However, in those 
studies preparation of the cell suspension differed from 
that of the first clinical report by Strasser et al.47 
Myoblasts were suspended in 1.4 mL of Dulbecco’s mod-
ified Eagle medium (DMEM)/F12 with 20% autologous 
serum, and fibroblasts were in 1 mL DMEM/F12 with 
20% autologous serum mixed with 2.5 mL collagen 
(Contigen, Bard, Covington, GA, USA) as the carrier ma-
terial.48 The fractional benefit of myoblasts versus fibro-
blasts versus collagen used in the mixed cell plus collagen 
injection approach is unclear. Further randomized, con-
trolled studies are necessary to clarify the benefit of 
mixed cellular plus collagen injection therapy.
Carr et al. reported the first trial of pure cellular 
clinical therapy with MDSCs obtained from a lateral 
thigh biopsy, and this represented the first trial of 
North American SUI patients.51 Eight patients received 
treatment using either a transurethral or periurethral 
injection into the middle urethra. The mean follow-up 
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period in this group was 16.5 months, and improvement 
in SUI was observed in five of eight women, with one 
achieving total continence. Improvement and cure con-
tinued at a median of 10 months with no serious ad-
verse events reported.51 Onset of improvement was at 
3–8 months after the injection suggesting that restoring 
muscle function may be the mechanism of action. Deeper 
delivery of MDSCs into the external sphincter appears to 
be important for a successful outcome.
The myofiber implantation procedure and injection 
of minced muscle are simple methods and may repre-
sent alternatives to traditional methods of muscle precur-
sor cell injections using cultured cells that require complex 
organization in clinical settings. Currently, a phase I clinical 
trial (NCT00472069, http://ClinicalTrials.gov) is investi-
gating the myofiber implantation procedure for SUI. The 
efficacy of clinical aspects of direct muscle implantation 
should be available in the near future.
7.  Conclusions
The use of SCs appears to be a major step in the right 
direction. However, there are several points that have to 
be clarified. First, costs and benefits should be consid-
ered and discussed when comparing these procedures 
with the gold standard treatment, the long-term efficacy 
of which is widely demonstrated. Furthermore, the cur-
rent clinical trial results came from the same research 
group in Austria.47–50 These data need to be reconfirmed 
in other centers and groups in terms of both efficacy and 
safety, especially after the current retraction of their 
publication in Lancet.52 Considering the etiology of SUI, 
which is currently believed to be intrinsic sphincter defi-
ciency and urethral hypermobility, SC injections alone 
or in combination with the traditional mid-urethral 
tension-free vaginal sling might be effective in treating 
most patients with SUI. Recent progress in tissue engi-
neering suggests that engineered urological tissue and 
cell therapy may have clinical applicability.19 Hopefully, 
the clinical translation in the field of urology may occur 
in the next decade.
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